
Symeres announces acquisition of DGr Pharma
Ella Day | September 11, 2025 | News story | Medical Communications, Research and Development |Â Â DGr Pharma, Symeres, biopharma, contract researchÂ
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug development-focused consultancy.
The acquisition will expand Symeres’ integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.
DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development.
Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance and regulatory submissions. DGr Pharma has deep expertise in small and large molecules including antibodies, ADCs and oligonucleotides.
Guillaume Jetten, CEO of Symeres, commented: “This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma’s expertise enhances our scientific capabilities, allowing us to better support our clients’ evolving needs.”
Kees Groen, Founder and CEO of DGr Pharma, added: “This is an exciting new chapter for DGr Pharma. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”
Related Content

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …

BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …

University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase …






